Abstracts Archive - Page 37 of 2425 - ACR Meeting Abstracts

Abstract Number: 0303 • ACR Convergence 2024
Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris¹, Jerry Bagel², Yu-Huei Huang³, Andrew E. Pink⁴, Stephen K. Tyring⁵, Georgios Kokolakis⁶, Amy M. DeLozier⁷, Daniel Kakaley⁸, Shu Li⁹, Yaung-Kaung Shen¹⁰, Takayuki Ota⁷ and Robert Bissonnette¹¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Psoriasis Treatment Center of Central NJ, East Windsor, NJ, ³Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), ⁴NHS Foundation Trust Great Maze Pond, London, United Kingdom, ⁵Center for Clinical Studies, Webster, TX, ⁶Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Innovaderm Research, Montreal, QC, Canada
Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
Abstract Number: 0256 • ACR Convergence 2024
Anti-TNF Therapy as a Potential Risk of Leishmania Infections
Gloria Albaladejo Paredes¹, Alicia Pérez González¹, Esther Monleón Acosta¹, Jose Andrés Rodríguez Fernández¹, Pedro José Manuel Hernández¹, Carlos Fernández Díaz¹, María Rosario Oliva Ruíz¹, Jose María Andreu Ubero², Paloma Valentina Castillo Dayer², Edgar Soriano Navarro³, David Pérez Parra⁴, Claudia Alejandra Capozzi², María Rocío González Molina⁵, José Francisco Orts Paco⁶, José Pablo Serrano Serra⁶ and Vicente Cogolludo Campillo², ¹Hospital Universitario Santa Lucía, CARTAGENA, Spain, ²Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain, ³Hospital Universitario Santa Lucía, Murcia, Murcia, Spain, ⁴Hospital Universitario Santa Lucía, Murcia, ⁵Hospital Reina Sofía, Murcia, Murcia, Spain, ⁶Hospital Universitario Reina Sofía, Murcia, Murcia, Spain
Background/Purpose: Leishmaniasis is an infectious disease caused by protozoon that occurs endemically in the Mediterranean Basin and South America and can affects to travellers to…
Abstract Number: 0243 • ACR Convergence 2024
Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment
Eve-Kai Raussi, Maigi Eisen, Küllike Palk and Marge Kütt, North Estonia Medical Centre Foundation, Tallinn, Estonia
Background/Purpose: Immune response in patients with immune-mediated inflammatory diseases (IMID) is compromised. As SARS-CoV-2 vaccine trials excluded patients on immunosuppressive therapy, data about vaccination efficacy…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 0252 • ACR Convergence 2024
Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
Aurélien Chepy¹, Michaël Genin², Louis Terriou³, Cécile Chenivesse⁴, Delphine Staumont-Sallé⁵, Hélène Zéphir⁶, Peggy philippe⁷, Guillaume Lefevre⁸, Sarah Stabler⁹, Eric HACHULLA³, David Launay¹⁰ and Vincent Sobanski³, ¹Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, ²Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, F-59000, France., Lille, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille, France, ⁴Centre de Référence Constitutif des Maladies Pulmonaires Rares, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille 59000, France., Lille, France, ⁵Service de dermatologie CHU Lille Université de Lille Lille France., Lille, France, ⁶Department of Neurology, CRC-SEP, CHU of Lille, Lille, France., Lille, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France., Lille, France, ⁸CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, ⁹CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France; Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Lille, France, ¹⁰CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille Cedex, France
Background/Purpose: Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells,…
Abstract Number: 0319 • ACR Convergence 2024
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Farbod Moghaddam¹, Mark Tarnopolsky², Valérie Leclair³, marie Hudson³, Ross Mitchell⁴, Katherine Buhler¹, Erin Hatcher⁵, Meifeng Zhang¹, Antoine Dufour¹, Luiz de Almeida¹, Marvin Fritzler⁶ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, Canada, ⁵McMaster University, Hamilton, Canada, ⁶Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
Abstract Number: 0306 • ACR Convergence 2024
Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Aleydis Gonzalez Melendez¹, Rebeca L. Polina-Lugo¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Osvaldo Uresti³, Ricardo I. de la Rosa-Vazquez³, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
Abstract Number: 0269 • ACR Convergence 2024
Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Yiling Zhang¹, Sara Tedeschi², Abhishek Abhishek³, Owen Hensey⁴, David Grossberg⁵, Ken Cai⁶, Beverley Shea⁷, Jasvinder Singh⁸, Robin Christensen⁹, Teodora Serban¹⁰, Edoardo Cipolletta¹¹, Konstantinos Parperis¹², César Díaz¹³, Geraldine McCarthy¹⁴, Fabio Becce¹⁵, Tamer A Gheita¹⁶, Silvia Sirotti¹⁷, Sara Nysom Christiansen¹⁸, Luis Coronel Tarancon¹⁹, Lisa Stamp²⁰, Yousra H Abdel-Fattah²¹, Tristan Pascart²², Georgios Filippou¹⁷, Lih En Hong²³, John FitzGerald²⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Brigham and Women's Hospital, Boston, MA, ³University of Nottingham, Nottingham, United Kingdom, ⁴OMERACT patient research partner, Dublin, Ireland, ⁵OMERACT patient research partner, Maryland, ⁶Westmead Hospital, Sydney, New South Wales, Australia, ⁷Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁸Baylor College of Medicine, Birmingham, AL, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Ospedale La Colletta, Bucharest, Romania, ¹¹Polytechnic University of Marche, Ancona, Italy, ¹²University of Cyprus Medical School, Nicosia, Cyprus, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁵Lausanne University Hospital (CHUV), Lausanne, Switzerland, ¹⁶Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁷IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ¹⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ¹⁹Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ²⁰University of Otago, Christchurch, Christchurch, New Zealand, ²¹Alexandria University, Alexandria, Egypt, ²²Lille Catholic University, Lille, France, ²³Royal Adelaide Hospital, Unley Park, South Australia, Australia, ²⁴UCLA, Los Angeles, CA
Background/Purpose: To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for long-term studies of calcium pyrophosphate deposition (CPPD) disease.Methods:…
Abstract Number: 0277 • ACR Convergence 2024
Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation
Jennifer Lee¹ and Ah Young Choi², ¹seoul st mary's hospital, Seoul, South Korea, ²The Cactholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Mesenchymal stem cells (MSCs) have anti-inflammatory properties and have been implicated in several inflammatory diseases. Acute gout is initiated by IL-1β produced by monosodium…
Abstract Number: 0542 • ACR Convergence 2024
Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Clementina López Medina¹, Sofia Ramiro², Dafne Capelusnik³ and Anna Molto⁴, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Leiden University Medical Center, Bunde, Netherlands, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
Abstract Number: 0014 • ACR Convergence 2024
Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Kaiyuan Zi and Juan Liang, GemPharmatech, San Diego
Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…
Abstract Number: 0209 • ACR Convergence 2024
Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study
Emily Grace, Sarah Green, Nikol Nikolova, Ashley Suh, Ryan Moore, Hank Domenico, Allison McCoy and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across specialties. We previously developed and validated a risk model to predict risk of developing…
Abstract Number: 0353 • ACR Convergence 2024
Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Joy Buie¹, Michael Fisher¹, Hannah Tlydsley², Kristen Backor² and Karen Costenbader³, ¹Lupus Foundation of America, Washington, DC, ²Charles River Associates, San Francisco, CA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…
Abstract Number: 0373 • ACR Convergence 2024
Enhancing Lupus Patient Education and Support at Kings County Hospital
Dmytro Gatsak¹, Jayashree Gandhi¹, Aleksander Feoktistov², Eugeniya Golub³ and Michael Trevisonno⁴, ¹Kings County Hospital/ SUNY Downstate Medical Center, Brooklyn, NY, ²Kings County Hospital Center/ H+H NYC, Brooklyn, NY, ³Kings County Hospital/ SUNY Downstate Medical Center, Staten Island, NY, ⁴State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Kings County Hospital, located in Brooklyn, New York, sees an estimated 243 patients with Systemic Lupus Erythematosus (SLE) annually. The patient demographic is predominantly…
Abstract Number: 0360 • ACR Convergence 2024
What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study
Cécile Gaujoux-Viala¹, Emmanuelle Dernis², Eric Senbel³ and René-Marc Flipo⁴, ¹CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³Cabinet de Rhumatologie, Marseille, France, ⁴Hôpital Roger Salengro, France, Lille, France
Background/Purpose: Treatment adherence is a major challenge in chronic inflammatory rheumatic diseases, particularly rheumatoid arthritis (RA), with adherence rates ranging from 30 to 80%. Given…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].